In a move that has sent shockwaves through both the medical and financial sectors, prediction market platforms Kalshi and Polymarket have begun offering sports-style betting on the outcomes of clinical drug trials and U.S. Food and Drug Administration (FDA) approval decisions. The new markets allow anyone with an account to wager on whether experimental drugs will succeed in late-stage trials or receive regulatory green lights—a development that critics are calling “ghastly” and potentially dangerous.

The New Betting Markets

Kalshi, a federally regulated prediction exchange, announced this week that it would let users bet on a range of clinical trial endpoints and FDA decisions, including whether specific drugs will meet primary efficacy goals or receive accelerated approval. Polymarket, a decentralized crypto-based platform, has similarly added contracts tied to drug development milestones. The offerings are structured like traditional betting markets: users buy shares in a binary outcome, and prices fluctuate based on perceived probability.

According to Forbes, this marks the first time that such detailed biomedical outcomes have been made available for public speculation. The Spokesman-Review described the initiative as “sports-style betting on drug trial results,” emphasizing the gamification of medical research. Seeking Alpha also reported on the development, noting that the markets could attract significant trading volume given the high stakes involved.

Critics Sound the Alarm

Researchers and bioethicists were quick to condemn the move. NPR quoted researchers warning that betting on clinical trials “could incentivize insider trading and interfere with drug development.” The underlying concern is that professionals with access to non-public data—such as clinical trial investigators, pharmaceutical company employees, or even FDA reviewers—might exploit their knowledge for financial gain, undermining the integrity of the regulatory process.

“This is a ghastly idea that commodifies the suffering of patients and creates dangerous incentives,” said one bioethicist in an MSN report on the controversy.

The MSN headline “Kalshi Defends Plan to Bet on Lives of Cancer Patients” captured the raw emotional response: many see the markets as profiting from the desperation of seriously ill patients. A particularly sensitive point is that some clinical trials are placebo-controlled, meaning bets are effectively on whether patients receiving a placebo will fare worse than those on the experimental treatment—a “life and death” wager in the eyes of critics.

Defenders: A Tool for Information

Kalshi and Polymarket, however, adopt a different stance. They argue that prediction markets have a proven track record of aggregating information and providing early signals about future events. In a defense echoed by multiple sources, the companies say they are offering a service to patients and the public by synthesizing available data into a tradable, transparent probability.

“Kalshi and Polymarket say they provide valuable information to patients,” NPR noted, summarizing the platforms’ position.

They point to similar markets in politics, sports, and even epidemiology—where Polymarket earned attention during the COVID-19 pandemic for predicting case counts and vaccine timelines. Defenders argue that if individuals can bet on elections or interest rate decisions, there is no ethical distinction preventing them from wagering on drug approvals, especially since such contracts can hedge risks for biotech investors and patients who rely on a drug’s success.

Ethical and Regulatory Questions

This new frontier raises a host of regulatory and ethical questions. While Kalshi is regulated by the Commodity Futures Trading Commission (CFTC) as a designated contract market, the CFTC has not yet issued specific guidance on biomedical outcome markets. Polymarket is offshore and less transparent, creating a regulatory gray area that investigators say is ripe for abuse.

Insider trading concerns are not merely theoretical. In 2021, the U.S. Securities and Exchange Commission brought charges against individuals who traded on confidential information about a failed clinical trial for a COVID-19 drug. Extending betting markets to drug approvals could multiply such opportunities for insider trading, particularly in countries where clinical trial data are not always stringently protected.

Furthermore, there is a concern that betting could influence the trial itself. For instance, if a large number of bettors take a position, the financial incentive could pressure investigators to manipulate endpoints or delay reporting unfavorable results—a scenario that could harm patient safety and erode trust in medical research.

A Changing Landscape for Drug Development

Despite the backlash, the move is part of a wider trend toward “event contracts” on real-world outcomes. Kalshi has already offered markets on everything from Federal Reserve decisions to inflation numbers. Polymarket has become a go-to source for election prognostication. Expanding into healthcare is a natural next step.

The pharmaceutical industry is watching closely. If these markets gain liquidity, they could provide real-time sentiment on drug candidates, which might benefit investors and even inform clinical trial design. However, the risk is that they turn medical research into a spectator sport, where profits take precedence over patient welfare.

Key Concerns Raised by Researchers & Ethicists

• Insider trading: Access to non-public trial data could be exploited for financial gain.
• Interference: Betting incentives might lead to data manipulation or delayed release of unfavorable results.
• Patient exploitation: Commodifying the outcomes of vulnerable patients is widely seen as unethical.
• Regulatory gaps: Existing futures and commodities laws do not explicitly address biomedical outcome markets.

What Experts Are Saying

Writing for STAT News, which covered the story in its “Pharmalittle” newsletter, industry analysts noted that this is another sign of the financialization of healthcare. The likely outcome, they argue, is a renewed push for regulatory clarity. The CFTC could choose to restrict or prohibit such contracts, or it could embrace them with safeguards.

Meanwhile, the founders of Kalshi and Polymarket remain defiant. In a statement quoted by several outlets, they asserted that their platforms are “on the right side of history” and that information from prediction markets has helped society make better decisions during times of uncertainty. They also emphasize that they have no intent to harm patients, merely to democratize information.

The controversy is far from resolved. As the platforms prepare to launch their first drug-trial contracts, many will be watching to see whether this experiment in financial innovation becomes a valuable insight engine or a cautionary tale about the dangers of unrestrained speculation.